A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 164,800 shares of INZY stock, worth $585,040. This represents 0.0% of its overall portfolio holdings.

Number of Shares
164,800
Previous 187,839 12.27%
Holding current value
$585,040
Previous $837,000 2.87%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$4.31 - $6.0 $99,298 - $138,234
-23,039 Reduced 12.27%
164,800 $861,000
Q2 2024

Aug 09, 2024

BUY
$4.33 - $7.31 $61,221 - $103,356
14,139 Added 8.14%
187,839 $837,000
Q1 2024

May 13, 2024

SELL
$4.14 - $7.66 $185,472 - $343,168
-44,800 Reduced 20.5%
173,700 $1.33 Million
Q4 2023

Feb 13, 2024

SELL
$2.71 - $4.5 $208,962 - $346,986
-77,108 Reduced 26.08%
218,500 $931,000
Q3 2023

Nov 14, 2023

BUY
$4.09 - $7.0 $230,708 - $394,856
56,408 Added 23.58%
295,608 $1.24 Million
Q2 2023

Aug 11, 2023

BUY
$4.93 - $6.74 $261,782 - $357,894
53,100 Added 28.53%
239,200 $1.33 Million
Q1 2023

May 12, 2023

SELL
$1.3 - $5.73 $94,640 - $417,144
-72,800 Reduced 28.12%
186,100 $1.07 Million
Q4 2022

Feb 13, 2023

BUY
$1.05 - $2.82 $108,675 - $291,870
103,500 Added 66.6%
258,900 $272,000
Q3 2022

Nov 14, 2022

BUY
$2.57 - $5.45 $95,347 - $202,195
37,100 Added 31.36%
155,400 $416,000
Q2 2022

Aug 12, 2022

BUY
$3.2 - $5.96 $340,480 - $634,144
106,400 Added 894.12%
118,300 $564,000
Q1 2022

May 13, 2022

BUY
$3.87 - $7.55 $46,053 - $89,845
11,900 New
11,900 $49,000

Others Institutions Holding INZY

About Inozyme Pharma, Inc.


  • Ticker INZY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,145,700
  • Market Cap $143M
  • Description
  • Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...
More about INZY
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.